Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

First Posted Date
2011-05-18
Last Posted Date
2018-09-18
Lead Sponsor
Michaela Liedtke
Target Recruit Count
14
Registration Number
NCT01355705
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

First Posted Date
2011-05-12
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
18
Registration Number
NCT01352962
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

First Posted Date
2011-05-11
Last Posted Date
2024-08-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT01351896
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

First Posted Date
2011-05-06
Last Posted Date
2019-01-15
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
19
Registration Number
NCT01349569
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

First Posted Date
2011-05-06
Last Posted Date
2023-06-28
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
11
Registration Number
NCT01348919
Locations
🇺🇸

Teva Investigational Site 1, Augusta, Georgia, United States

🇳🇿

Teva Investigational Site 204, Auckland, New Zealand

🇺🇸

Teva Investigational Site 2, Houston, Texas, United States

and more 5 locations

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Phase 1
Terminated
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Lenalidomide
Drug: Sorafenib
First Posted Date
2011-05-05
Last Posted Date
2015-08-31
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
5
Registration Number
NCT01348503
Locations
🇺🇸

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry

Completed
Conditions
Myelodysplastic Syndrome
First Posted Date
2011-05-05
Last Posted Date
2019-11-18
Lead Sponsor
Celgene
Target Recruit Count
149
Registration Number
NCT01347944
Locations
🇮🇹

Dipartimento Onco - Ematologico Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo, Alessandria, Italy

🇮🇹

Ematologia Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, Italy

🇮🇹

Ematologia A.O. Ospedale Riuniti di Bergamo, Bergamo, Italy

and more 42 locations

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Phase 1
Terminated
Conditions
Urinary Bladder Neoplasms
Interventions
Drug: Lenalidomide
First Posted Date
2011-04-27
Last Posted Date
2019-04-23
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
9
Registration Number
NCT01342172
Locations
🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

National Cancer Institute, Bethesda, Maryland, United States

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

First Posted Date
2011-04-14
Last Posted Date
2022-09-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
748
Registration Number
NCT01335399
Locations
🇮🇱

Local Institution - 4959, Kfar Saba, Israel

🇷🇴

Local Institution - 5352, Bucuresti, Romania

🇵🇱

Local Institution - 5254, Gdansk, Poland

and more 232 locations

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Phase 2
Active, not recruiting
Conditions
Non Hodgkin's Lymphoma
Interventions
Drug: Rituximab
Drug: Lenalidomide
First Posted Date
2011-03-16
Last Posted Date
2023-09-01
Lead Sponsor
University of California, Davis
Target Recruit Count
30
Registration Number
NCT01316523
Locations
🇺🇸

University of California Davis Cancer Center, Sacramento, California, United States

🇺🇸

Sutter Pacific Medical Foundation, Santa Rosa, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy